title: Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease.
abstract: BACKGROUND
  Oxidative stress is heavily implicated in the pathogenic process of Parkinson's disease. Varying capacity to detoxify radical oxygen species through induction of phase II antioxidant enzymes in substantia nigra may influence disease risk. Here, we hypothesize that variation in NFE2L2 and KEAP1, the genes encoding the two major regulators of the phase II response, may affect the risk of Parkinson's disease.
  
  
  METHODS
  The study included a Swedish discovery case-control material (165 cases and 190 controls) and a Polish replication case-control material (192 cases and 192 controls). Eight tag single nucleotide polymorphisms representing the variation in NFE2L2 and three representing the variation in KEAP1 were chosen using HapMap data and were genotyped using TaqMan Allelic Discrimination.
  
  
  RESULTS
  We identified a protective NFE2L2 haplotype in both of our European case-control materials. Each haplotype allele was associated with five years later age at onset of the disease (p = 0.001) in the Swedish material, and decreased risk of PD (p = 2 x 10(-6)), with an odds ratio of 0.4 (95% CI 0.3-0.6) for heterozygous and 0.2 (95% CI 0.1-0.4) for homozygous carriers, in the Polish material. The identified haplotype includes a functional promoter haplotype previously associated with high transcriptional activity. Genetic variation in KEAP1 did not show any associations.
  
  
  CONCLUSIONS
  These data suggest that variation in NFE2L2 modifies the Parkinson's disease process and provide another link between oxidative stress and neurodegeneration.
authors.affiliation: Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Blå stråket 15, 413 45 Gothenburg, Sweden. malin.vonotter@gu.se
authors.forename: Malin
authors.initials: M
authors.lastname: von Otter
authors.forename: Sara
authors.initials: S
authors.lastname: Landgren
authors.forename: Staffan
authors.initials: S
authors.lastname: Nilsson
authors.forename: Dragana
authors.initials: D
authors.lastname: Celojevic
authors.forename: Petra
authors.initials: P
authors.lastname: Bergström
authors.forename: Anna
authors.initials: A
authors.lastname: Håkansson
authors.forename: Hans
authors.initials: H
authors.lastname: Nissbrandt
authors.forename: Marek
authors.initials: M
authors.lastname: Drozdzik
authors.forename: Monika
authors.initials: M
authors.lastname: Bialecka
authors.forename: Mateusz
authors.initials: M
authors.lastname: Kurzawski
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Michael
authors.initials: M
authors.lastname: Nilsson
authors.forename: Ola
authors.initials: O
authors.lastname: Hammarsten
authors.forename: Henrik
authors.initials: H
authors.lastname: Zetterberg
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006239:Haplotypes; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D000072019:Kelch-Like ECH-Associated Protein 1; D008297:Male; D008875:Middle Aged; D051267:NF-E2-Related Factor 2 / Q000235:genetics*; D018384:Oxidative Stress; D010300:Parkinson Disease / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; C431364:KEAP1 protein, human; D000072019:Kelch-Like ECH-Associated Protein 1; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human